Suppliers and packagers for CABENUVA KIT

CABENUVA KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888	NDA	ViiV Healthcare Company	49702-240-15	1 KIT in 1 CARTON (49702-240-15) * 3 mL in 1 VIAL (49702-238-01) * 3 mL in 1 VIAL (49702-243-02)	2021-01-21
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888	NDA	ViiV Healthcare Company	49702-253-15	1 KIT in 1 CARTON (49702-253-15) * 2 mL in 1 VIAL (49702-245-01) * 2 mL in 1 VIAL (49702-249-02)	2021-01-21
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888	NDA	ViiV Healthcare Company	49702-266-63	1 KIT in 1 CARTON (49702-266-63) * 3 mL in 1 VIAL (49702-238-64) * 3 mL in 1 VIAL (49702-243-61)	2025-01-21

Suppliers for the Pharmaceutical Drug: CABENUVA KIT

Last updated: July 27, 2025

Introduction

CABENUVA KIT is a groundbreaking combination therapy for the treatment of HIV-1 infection, marketed primarily by ViiV Healthcare. The drug combines long-acting cabotegravir and rilpivirine, administered via intramuscular injections once every two months, revolutionizing HIV management paradigms by reducing pill burden and improving adherence. The manufacturing and supply chain intricacies of CABENUVA are complex, involving various suppliers across different value chain stages, including active pharmaceutical ingredient (API) production, formulation, packaging, and distribution. This article provides a comprehensive analysis of the key suppliers involved in the production of CABENUVA KIT, highlighting their roles, strategic importance, and implications for the pharmaceutical supply ecosystem.

---

1. Active Pharmaceutical Ingredient (API) Suppliers

Cabotegravir and Rilpivirine APIs are the core components of CABENUVA.

a. Cabotegravir API Suppliers

Cabotegravir, an integrase strand transfer inhibitor (INSTI), is synthesized through proprietary chemical processes. Prime API manufacturing partners have historically been located in regions with strong chemical manufacturing capabilities, such as China and India.

• Hetero Labs (India): Known for producing bulk APIs with a focus on antiretroviral agents, Hetero has been identified as a potential supplier or collaborator for cabotegravir production. Their facilities comply with global regulatory standards, including cGMP.

• Mynkee Pharma (China): Emerging as a significant player in generic and API manufacturing, Mynkee Pharma has capacity for complex molecular APIs like cabotegravir, supporting global demand.

• ViiV Healthcare’s In-House Capabilities: It is common for biopharmaceutical companies to retain some API manufacturing capabilities or strategic alliances for critical compounds. ViiV has invested in securing supply chains for key APIs, and reports suggest they may have biosynthesis and manufacturing partnerships.

b. Rilpivirine API Suppliers

As a non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine requires specific synthetic routes.

• Jicheng Pharmaceutical (China): Recognized for rilpivirine API manufacturing, Jicheng supplies both branded and generic formulations globally, maintaining quality standards aligned with regulatory requirements.

• Sun Pharmaceutical Industries (India): Given their extensive portfolio in antiretrovirals, Sun Pharma is another potential supplier of rilpivirine API, providing economies of scale depending on demand.

---

2. Formulation and Finished Dosage Form Suppliers

While CABENUVA KIT is a combination of two APIs administered via intramuscular injections, the formulation process involves specialized manufacturing, vial filling, and packaging.

• ViiV Healthcare Manufacturing Facilities

ViiV operates several manufacturing units across North America, Europe, and Asia, with expertise in sterile injectable formulations for long-acting HIV therapies.

• Contract Manufacturing Organizations (CMOs)

  • Samsung BioLogics (South Korea): Known for large-scale biologics manufacturing, Samsung BioLogics reportedly plays a role in producing or filling vials of CABENUVA components.

  • Catalent (USA/Europe): As a leading CMO specializing in sterile injectables and complex formulations, Catalent may hold manufacturing contracts for vial filling and packaging.

  • Boehringer Ingelheim (Germany): The company has capabilities in sterile drug manufacturing and could be involved in the fill-finish process.

---

3. Packaging, Labeling, and Distribution Suppliers

• Packaging Suppliers

  • Gerresheimer (Germany): Supplies glass vials and stoppers suited for long-acting injectable medications.

  • Nipro Corporation (Japan): Provides rubber stoppers, rubber closures, and related packaging components suited for sterile injectable drugs.

• Distribution Partners

ViiV Healthcare's distribution network spans global regions, often partnering with specialized logistics providers to ensure cold chain integrity and timely delivery.

• CSafe Global: Provides temperature-controlled shipping containers.

• UPS Healthcare: Manages global distribution logistics, ensuring compliance with storage temperature requirements, especially for long-acting injectables.

---

4. Supply Chain and Strategic Considerations

The supply landscape for CABENUVA KIT is influenced by several factors:

• Regulatory Approvals and Quality Assurance: Suppliers must meet stringent cGMP standards, with some manufacturing stages requiring FDA, EMA, or other global regulatory approvals.

• Geopolitical Dynamics: The reliance on suppliers in China and India exposes the supply chain to geopolitical risks, trade tariffs, and export restrictions, which could impact production timelines.

• Supply Chain Security: ViiV Healthcare’s strategy involves diversifying suppliers and integrating vertical manufacturing to mitigate risks associated with API shortages or manufacturing disruptions.

• Patent and Licensing Agreements: As a proprietary combination therapy, ViiV ensures that supplier agreements restrict the production of APIs to licensed manufacturers to prevent patent infringement and ensure quality.

---

5. Future Perspectives and Market Implications

• Emerging API Suppliers: As demand for CABENUVA increases, new suppliers may emerge in regions like Southeast Asia or South America, supported by favorable production cost structures and capacity expansion.

• Supply Chain Resilience: The COVID-19 pandemic underscored the need for diversified supply chains, prompting ViiV and other pharmaceutical companies to strengthen supplier relationships and explore local manufacturing options.

• Technological Advancements: Improvements in synthetic chemistry and biotechnological processes could enable more efficient and sustainable API production, reducing costs and lead times.

---

Key Takeaways

• Diverse Supplier Base: The production of CABENUVA KIT involves multiple suppliers specializing in APIs, formulation, packaging, and distribution, predominantly in China, India, and Europe.

• Strategic Partnerships: ViiV Healthcare’s reliance on CMOs and strategic suppliers underscores the importance of robust vendor management to ensure quality and supply continuity.

• Global Risks: Geopolitical, regulatory, and pandemic-related challenges threaten supply stability, prompting proactive diversification and contingency planning.

• Industry Trends: Increasing investment in local manufacturing and capacity expansion is likely to shape the future of CABENUVA’s supply chain.

---

FAQs

1. Who are the primary API suppliers for cabotegravir and rilpivirine?
Major API suppliers include companies like Hetero Labs, Mynkee Pharma, Jicheng Pharmaceutical, and Sun Pharmaceutical Industries, primarily operating in India and China.

2. Does ViiV Healthcare manufacture APIs in-house?
While some strategic API manufacturing capabilities may exist within ViiV, much of the API supply is managed through partnerships with third-party manufacturers and CMOs, particularly in Asia.

3. What role do CMOs play in the production of CABENUVA kits?
CMOs handle formulation, sterile manufacturing, vial filling, and packaging, ensuring quality standards and scalability to meet global demand.

4. How does supply chain risk impact CABENUVA availability?
Dependence on regional manufacturing hubs introduces risks like geopolitical tensions and supply disruptions, challenging continuous availability and prompting diversification.

5. Are there plans to localize the manufacturing of CABENUVA components?
Industry trends indicate increasing efforts to localize production in different regions to enhance supply resilience, though specific plans for CABENUVA are not publicly detailed.

---

References

1. ViiV Healthcare. (2023). Product Information: CABENUVA.
2. GlobalData. (2023). Pharmaceutical API Market Analysis.
3. U.S. Food and Drug Administration (FDA). GMP Inspections and Standards.
4. Industry Reports. (2022). Contract Manufacturing Organizations in the Pharmaceutical Sector.
5. Company websites: Hetero Labs, Mynkee Pharma, Jicheng Pharmaceutical, Sun Pharmaceutical Industries, Samsung BioLogics, Catalent, Boehringer Ingelheim.